2025 Q4 -tulosraportti
69 päivää sitten
‧23 min
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 5 999 | - | - | ||
| 1 | - | - | ||
| 1 999 | - | - | ||
| 2 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·13 t sittenThe same short sellers who wreaked havoc with Circio ? In that case, the consolation is that the share price will go up again.
·1 t sittenThe share cannot be shorted btw.
1 päivä sitten1 päivä sitten
·16.4.What is the status of phase 3 and the financing? This was said by Verrica yesterday at the 25th Annual Needham Virtual Healthcare Conference yesterday: "Phase three program is ready to kick off. The protocols have been submitted, and the protocol synopsis has been aligned with the agency. The development comprehensive program has been aligned with the agency. We are working now on CRO bids and finalization of a definitive protocol. What study start-up activities might look like. Right now we're also exploring some non-dilutive opportunities for funding that program, whether it's partnership, etc. Given the size and scope of the potential that program, partners with global reach could be very helpful. We have access to YCANTH globally. BCC, all global rights, including Japan. It presents a number of opportunities to find the right type of co-development or other partners to advance that program or to use any proceeds from a YCANTH partnership to help fund that program. We feel very fortunate with where we are. You know, financially. With the BCC program, the Q1 work program, with the funding provided by Torii and the growing revenue base in YCANTH for Molluscum and the cash runway into next year. We are exploring all those options. The what we need to do over the balance of this year for VP-315 is de minimis in cost relative to conduct the study, but it does take time to be Phase 3 ready. So we're continuing to do those efforts on the CMC side and the regulatory and development side to be ready to start a trial, perhaps as early as the end of this year." I also understood that the YCANTH sales trend for the first 3 months in 2026 was positive, and thus also increases the possibilities for Verrica to largely finance VP-315 itself.... possibly with financing from global partners either for VP-315 and/or YCANTH. In summary, things take time.... but several opportunities have emerged for how Verrica can get phase 3 financed. The most important thing is that it starts up by the end of q1-2027, I think. Then the share price could rise significantly before Lytix might need additional capital.
·16.4.Verrica raised half a billion last year and has reported having cash runway until mid 2027, so there are no problems in the short term. However, it will be exciting already on Monday with the Atlas presentation in San Diego.
·15.4.I am so overdue in providing an update now regarding the start of phase 3 now! Nice with new hires and fair words, but now we really need a confirmation that Verrica is the right partner for Lytix! It seems they have such big problems themselves that the phase 3 study is not prioritized there!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
69 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13 t sittenThe same short sellers who wreaked havoc with Circio ? In that case, the consolation is that the share price will go up again.·1 t sittenThe share cannot be shorted btw.
- 1 päivä sitten1 päivä sitten
- ·16.4.What is the status of phase 3 and the financing? This was said by Verrica yesterday at the 25th Annual Needham Virtual Healthcare Conference yesterday: "Phase three program is ready to kick off. The protocols have been submitted, and the protocol synopsis has been aligned with the agency. The development comprehensive program has been aligned with the agency. We are working now on CRO bids and finalization of a definitive protocol. What study start-up activities might look like. Right now we're also exploring some non-dilutive opportunities for funding that program, whether it's partnership, etc. Given the size and scope of the potential that program, partners with global reach could be very helpful. We have access to YCANTH globally. BCC, all global rights, including Japan. It presents a number of opportunities to find the right type of co-development or other partners to advance that program or to use any proceeds from a YCANTH partnership to help fund that program. We feel very fortunate with where we are. You know, financially. With the BCC program, the Q1 work program, with the funding provided by Torii and the growing revenue base in YCANTH for Molluscum and the cash runway into next year. We are exploring all those options. The what we need to do over the balance of this year for VP-315 is de minimis in cost relative to conduct the study, but it does take time to be Phase 3 ready. So we're continuing to do those efforts on the CMC side and the regulatory and development side to be ready to start a trial, perhaps as early as the end of this year." I also understood that the YCANTH sales trend for the first 3 months in 2026 was positive, and thus also increases the possibilities for Verrica to largely finance VP-315 itself.... possibly with financing from global partners either for VP-315 and/or YCANTH. In summary, things take time.... but several opportunities have emerged for how Verrica can get phase 3 financed. The most important thing is that it starts up by the end of q1-2027, I think. Then the share price could rise significantly before Lytix might need additional capital.·16.4.Verrica raised half a billion last year and has reported having cash runway until mid 2027, so there are no problems in the short term. However, it will be exciting already on Monday with the Atlas presentation in San Diego.
- ·15.4.I am so overdue in providing an update now regarding the start of phase 3 now! Nice with new hires and fair words, but now we really need a confirmation that Verrica is the right partner for Lytix! It seems they have such big problems themselves that the phase 3 study is not prioritized there!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 5 999 | - | - | ||
| 1 | - | - | ||
| 1 999 | - | - | ||
| 2 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
2025 Q4 -tulosraportti
69 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13 t sittenThe same short sellers who wreaked havoc with Circio ? In that case, the consolation is that the share price will go up again.·1 t sittenThe share cannot be shorted btw.
- 1 päivä sitten1 päivä sitten
- ·16.4.What is the status of phase 3 and the financing? This was said by Verrica yesterday at the 25th Annual Needham Virtual Healthcare Conference yesterday: "Phase three program is ready to kick off. The protocols have been submitted, and the protocol synopsis has been aligned with the agency. The development comprehensive program has been aligned with the agency. We are working now on CRO bids and finalization of a definitive protocol. What study start-up activities might look like. Right now we're also exploring some non-dilutive opportunities for funding that program, whether it's partnership, etc. Given the size and scope of the potential that program, partners with global reach could be very helpful. We have access to YCANTH globally. BCC, all global rights, including Japan. It presents a number of opportunities to find the right type of co-development or other partners to advance that program or to use any proceeds from a YCANTH partnership to help fund that program. We feel very fortunate with where we are. You know, financially. With the BCC program, the Q1 work program, with the funding provided by Torii and the growing revenue base in YCANTH for Molluscum and the cash runway into next year. We are exploring all those options. The what we need to do over the balance of this year for VP-315 is de minimis in cost relative to conduct the study, but it does take time to be Phase 3 ready. So we're continuing to do those efforts on the CMC side and the regulatory and development side to be ready to start a trial, perhaps as early as the end of this year." I also understood that the YCANTH sales trend for the first 3 months in 2026 was positive, and thus also increases the possibilities for Verrica to largely finance VP-315 itself.... possibly with financing from global partners either for VP-315 and/or YCANTH. In summary, things take time.... but several opportunities have emerged for how Verrica can get phase 3 financed. The most important thing is that it starts up by the end of q1-2027, I think. Then the share price could rise significantly before Lytix might need additional capital.·16.4.Verrica raised half a billion last year and has reported having cash runway until mid 2027, so there are no problems in the short term. However, it will be exciting already on Monday with the Atlas presentation in San Diego.
- ·15.4.I am so overdue in providing an update now regarding the start of phase 3 now! Nice with new hires and fair words, but now we really need a confirmation that Verrica is the right partner for Lytix! It seems they have such big problems themselves that the phase 3 study is not prioritized there!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 5 999 | - | - | ||
| 1 | - | - | ||
| 1 999 | - | - | ||
| 2 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt